Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 164Carboplatin 136Cisplatin 84Paclitaxel 80Gemcitabine 77Pemetrexed 74Bevacizumab 65Docetaxel 54Fluorouracil 50Oxaliplatin 48Dexamethasone 45durvalumab 42atezolizumab 40Leucovorin 40130-nm albumin-bound paclitaxel 40Capecitabine 38Nivolumab 35Cetuximab 35Rituximab 33Cyclophosphamide 33Injections 31Fulvestrant 30venetoclax 28Prednisone 28Lenalidomide 27enzalutamide 26Irinotecan 25pomalidomide 24Letrozole 24daratumumab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Paroxetine × 30 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡